JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

Search

SCYNEXIS Inc

Închisă

0.77

Rezumat

Modificarea prețului

24h

Curent

Minim

0.76

Maxim

0.77

Indicatori cheie

By Trading Economics

Venit

-1.5M

-6.9M

Vânzări

1.1M

1.4M

Marjă de profit

-504.765

Angajați

28

EBITDA

-4.3M

-9.6M

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+419.48% upside

Statistici piață

By TradingEconomics

Capitalizare de piață

-2.1M

32M

Deschiderea anterioară

0.77

Închiderea anterioară

0.77

Scor tehnic

By Trading Central

Încredere

Weak Bullish Evidence

SCYNEXIS Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

24 oct. 2025, 18:41 UTC

Câștiguri

Procter & Gamble to Focus on Innovation, Not Discounts, to Attract Wary Shoppers - 2nd Update

24 oct. 2025, 18:31 UTC

Câștiguri

Correction to Procter & Gamble to Focus on Innovation

24 oct. 2025, 16:25 UTC

Principalele dinamici ale pieței

Obook Shares Rise, Company Secures New Money Transmitter Licenses

24 oct. 2025, 21:24 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

24 oct. 2025, 21:24 UTC

Market Talk

Moody's Sees France With Increased Risk of Political Dysfunction -- Market Talk

24 oct. 2025, 21:07 UTC

Câștiguri

The Score: Netflix, Amazon.com, Six Flags and More Stocks That Defined the Week -- WSJ

24 oct. 2025, 20:58 UTC

Câștiguri

S&P 500 Climbs to New Record on Strong Earnings -- WSJ

24 oct. 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

24 oct. 2025, 20:40 UTC

Câștiguri

Intel Expects Chip Shortages on Better PC Demand. Here's Why AMD Is Winning Too. -- Barrons.com

24 oct. 2025, 20:24 UTC

Câștiguri

General Dyamics Stock Rises on Earnings. Aerospace Was a Standout. -- Barrons.com

24 oct. 2025, 20:23 UTC

Câștiguri

General Dyamics Stock Rises on Earnings. Aerospace Was a Standout. -- Barrons.com

24 oct. 2025, 20:13 UTC

Câștiguri

These Stocks Moved the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

24 oct. 2025, 20:07 UTC

Market Talk

Different-Cell Imputation Rose Proportionally in September CPI -- Market Talk

24 oct. 2025, 19:40 UTC

Market Talk

Treasury Yields Mixed, Dollar Stronger Ahead of Fed Week -- Market Talk

24 oct. 2025, 19:35 UTC

Market Talk

Oil Rally on U.S. Russia Sanctions Loses Steam -- Market Talk

24 oct. 2025, 19:33 UTC

Câștiguri

IBM and Google Are Also Making Moves in Quantum. Don't Count Out the Bigger Players. -- Barrons.com

24 oct. 2025, 19:29 UTC

Market Talk

U.S. Natural Gas Ends Week Higher on Weather Outlook -- Market Talk

24 oct. 2025, 18:52 UTC

Câștiguri

Correction to GM Stock Soars to Record High. Earnings Were So Good, They Helped Ford. -- Barrons.com

24 oct. 2025, 18:41 UTC

Câștiguri

GM Stock Soars to Record High. Earnings Were So Good, They Helped Ford. -- Barrons.com

24 oct. 2025, 18:03 UTC

Câștiguri

Beyond Meat Stock Is on a Wild Ride. Why a Meme Rally Looks Undercooked. -- Barrons.com

24 oct. 2025, 18:02 UTC

Câștiguri

Progressive Stock Got Hit After Earnings. It's Time to Buy One of America's Great Companies. -- Barrons.com

24 oct. 2025, 18:00 UTC

Market Talk

U.S. Oil Rig Count Rises By Two to 420 -- Market Talk

24 oct. 2025, 16:57 UTC

Câștiguri

Ford Stock Has Quadrupled Tesla's Gains. What's Behind Its Meteoric Rise. -- Barrons.com

24 oct. 2025, 16:54 UTC

Market Talk

End to Canada-U.S. Trade Talks Not Seen Shifting Nearterm Outlook -- Market Talk

24 oct. 2025, 16:44 UTC

Market Talk
Câștiguri

Amazon Retail Looks Strong as Consumer Sentiment Improves -- Market Talk

24 oct. 2025, 16:39 UTC

Market Talk
Câștiguri

Amazon Sentiment Around AWS Seen as Improving in 3Q -- Market Talk

24 oct. 2025, 16:33 UTC

Câștiguri

These Stocks Are Moving the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

24 oct. 2025, 16:23 UTC

Câștiguri

These Stocks Are Moving the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

24 oct. 2025, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

24 oct. 2025, 16:07 UTC

Câștiguri

Ford Stock Has Quadrupled Tesla's Gains. What's Behind Its Meteoric Rise. -- Barrons.com

Comparație

Modificare preț

SCYNEXIS Inc Așteptări

Obiectiv de preț

By TipRanks

419.48% sus

Prognoză pe 12 luni

Medie 4 USD  419.48%

Maxim 4 USD

Minim 4 USD

În baza a 1 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruSCYNEXIS Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

1 ratings

1

Cumpărare

0

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

0.9307 / 0.9907Suport & Rezistență

Termen scurt

Weak Bullish Evidence

Termen mediu

Weak Bearish Evidence

Termen lung

No Evidence

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre SCYNEXIS Inc

SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases. The company has licensing and collaboration agreements with GlaxoSmithKline Intellectual Property (No. 3) Limited, Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC for the development, manufacture, and commercialization of ibrexafungerp. SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. The company was incorporated in 1999 and is headquartered in Jersey City, New Jersey.
help-icon Live chat